Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 23-30

  Larsen, R ^a,c   Ryder, L P ^a   Svejgaard, A ^a   Gniadecki, R ^b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Alefacept; CLA; NK T; Psoriasis; T cells

Indexed keywords

ALEFACEPT; ANTIGEN; CD161 ANTIGEN; CD2 ANTIGEN; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD45- CD27- T LYMPHOCYTE; CD45RA+ CD27- T LYMPHOCYTE; CD45RA- CD27+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; AGED; ANTIGENS, CD2; CD4-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; METHOTREXATE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 34250174816     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03380.x     Document Type: Article

References (27)

1. da Silva AJ, Brickelmaier M, Majeau GR et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002 168 : 4462 71.
2. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 345 : 248 55.
3. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003 139 : 1563 70.
4. Liu CM, McKenna JK, Krueger GG. Alefacept: a novel biologic in the treatment of psoriasis. Drugs Today (Barcelona) 2004 40 : 961 74.
5. Ortonne JP, Lebwohl M, Em GC. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003 13 : 117 23.
6. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002 29 : 415 26.
7. Prince HE, York J, Jensen ER. Phenotypic comparison of the three populations of human lymphocytes defined by CD45RO and CD45RA expression. Cell Immunol 1992 145 : 254 62.
8. Sanders ME, Makgoba MW, Sharrow SO et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 1988 140 : 1401 7.
9. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004 150 : 852 9.
10. Wallace DL, Beverley PC. Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells. Immunology 1990 69 : 460 7.
11. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000 292 : 519 21.
12. Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 2004 29 : 658 63.
13. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000 165 : 4076 85.
14. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 2000 24 : 212 25.
15. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005 174 : 164 73.
16. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004 4 : 231 7.
17. Reimann KA, Chernoff M, Wilkening CL, Nickerson CE, Landay AL. Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol 2000 7 : 352 9.
18. Lundgren A, Stromberg E, Sjoling A et al. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005 73 : 523 31.
19. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003 4 : 835 42.
20. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001 126 : 365 9.
21. Cooper JC, Morgan G, Harding S et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003 33 : 666 75.
22. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006 176 : 211 6.
23. Chamian F, Lowes MA, Lin SL et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005 102 : 2075 80.
24. Cauza K, Grassauer A, Hinterhuber G et al. FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma. J Invest Dermatol 2002 119 : 1074 9.
25. Rentenaar RJ, Heydendael VM, van Diepen FN, de Rie MA, ten Berge IJ. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol 2004 24 : 361 9.
26. Bohm I. Decrease of B-cells and autoantibodies after low-dose methotrexate. Biomed Pharmacother 2003 57 : 278 81.
27. Lee SY, Shim JY, Kim JH et al. Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+) CD4(+) T cells in children with severe atopic dermatitis. Allergy 2004 59 : 1129 30.